<DOC>
	<DOC>NCT00622635</DOC>
	<brief_summary>This study was conducted to provide detailed information on the efficacy of indacaterol in terms of its effect on spirometry assessed forced expiratory volume in 1 second (FEV1) over a 24 hour time period.</brief_summary>
	<brief_title>A Crossover Study to Determine the 24 Hour Lung Function Profile of Indacaterol in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases, Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
	<mesh_term>Salmeterol Xinafoate</mesh_term>
	<criteria>Diagnosis of chronic obstructive pulmonary disease (COPD) (moderatetosevere as classified by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) Guidelines, 2006) and: 1. Smoking history of at least 20 packyears 2. Postbronchodilator forced expiratory volume in 1 second (FEV1) &lt; 80% and â‰¥ 30% of the predicted normal value 3. Postbronchodilator FEV1/FVC (forced vital capacity) &lt; 70% Patients who have been hospitalized for a COPD exacerbation in the 6 weeks prior to screening or during the runin period Patients requiring longterm oxygen therapy (&gt; 15 hours a day) for chronic hypoxemia Patients who have had a respiratory tract infection within 6 weeks prior to screening Patients with concomitant pulmonary disease Patients with a history of asthma Patients with diabetes Type I or uncontrolled diabetes Type II Any patient with lung cancer or a history of lung cancer Any patient with active cancer or a history of cancer with less than 5 years diseasefree survival time Patients with a history of long QT syndrome or whose QTc interval (Bazett's) measured at screening or randomization is prolonged Patients who have been vaccinated with live attenuated vaccines within 30 days prior to screening or during the runin period Patients unable to successfully use a dry powder inhaler device or perform spirometry measurements Other protocoldefined inclusion/exclusion criteria applied to the study.</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>chronic obstructive pulmonary disease</keyword>
	<keyword>COPD</keyword>
	<keyword>indacaterol</keyword>
</DOC>